1. Home
  2. WHG vs NGEN Comparison

WHG vs NGEN Comparison

Compare WHG & NGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Westwood Holdings Group Inc

WHG

Westwood Holdings Group Inc

N/A

Current Price

$18.77

Market Cap

185.2M

Sector

Finance

ML Signal

N/A

Logo NervGen Pharma Corp. Common stock

NGEN

NervGen Pharma Corp. Common stock

N/A

Current Price

$2.14

Market Cap

200.0M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
WHG
NGEN
Founded
1983
2017
Country
United States
Canada
Employees
N/A
N/A
Industry
Investment Managers
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
185.2M
200.0M
IPO Year
2002
2018

Fundamental Metrics

Financial Performance
Metric
WHG
NGEN
Price
$18.77
$2.14
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$18.00
AVG Volume (30 Days)
16.8K
606.4K
Earning Date
04-30-2026
04-02-2026
Dividend Yield
3.58%
N/A
EPS Growth
203.85
N/A
EPS
0.25
N/A
Revenue
$97,762,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$75.16
N/A
Revenue Growth
3.21
N/A
52 Week Low
$14.70
$1.58
52 Week High
$20.97
$5.93

Technical Indicators

Market Signals
Indicator
WHG
NGEN
Relative Strength Index (RSI) 37.31 59.18
Support Level $18.30 $1.62
Resistance Level $18.64 $2.32
Average True Range (ATR) 0.48 0.15
MACD -0.10 -0.01
Stochastic Oscillator 19.46 53.41

Price Performance

Historical Comparison
WHG
NGEN

About WHG Westwood Holdings Group Inc

Westwood Holdings Group Inc manages investment assets and provides services for clients through subsidiaries. It operates its business through the Advisory and Trust segments. Its Advisory segment provides investment advisory services to corporate retirement plans, public retirement plans, endowments, foundations, individuals and the Westwood Funds, as well as investment sub-advisory services to mutual funds and its trust segment. The Trust segment offers trust and custodial services to its clients and its advisory segment sponsors common trust funds to institutions and high net-worth individuals. It generates maximum revenue from the Advisory segment. Geographically, it derives a majority of its revenue from the United States, and also has its presence in Canada.

About NGEN NervGen Pharma Corp. Common stock

NervGen Pharma Corp is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. The Company's principal business activity is the discovery, development and commercialization of neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. NervGen's initial target indication is SCI. The company's pipeline products include NVG-291 and NVG-300.

Share on Social Networks: